Market Overview:
The global hepatitis C treatment market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of hepatitis C, rising awareness about available treatments, and growing demand for better and more effective therapies. The global hepatitis C treatment market can be segmented on the basis of type into prescription-based and over-the-counter (OTC) therapies. The prescription-based therapies are further subsegmented into direct acting antivirals (DAAs) and interferon/ribavirin regimens. The DAA therapy is expected to witness the highest growth during the forecast period owing to its high efficacy rates and fewer side effects as compared to other therapies. On the basis of application, the market can be segmented into hospitals, clinics, and other settings such as home care or long term care facilities. Geographically, it can be divided into North America, Latin America, Europe Asia Pacific ,and Middle East & Africa . North America is estimated to account for a major share of this market in 2018 owing to factors such as early adoption of new technologies by healthcare providers in this region coupled with increasing prevalence of HCV infections among people who inject drugs (PWID).
Product Definition:
Hepatitis C Treatment is a process that helps to clear the hepatitis C virus from a person's body. It is important because it can help prevent liver damage, cancer, and even death.
Rx:
Rx is short for prescription. It's a term used in the healthcare industry to define the medicine given to a patient by a doctor or pharmacist after evaluating its medical necessity. In case of pharmaceutical products, rx refers to the generic version of any product sold under an active ingredient prescription by manufacturers or distributors authorized by the physician who prescribed it.
OTC:
OTC stands for Over-the-Counter and it's used to refer to medications that can be purchased without a prescription from a pharmacist in the store or through online sales. OTC drugs are usually for immediate use, e.g., pain relief medicines, cold & cough medicine, vitamins & minerals supplements; whereas prescription drugs are ordered by healthcare professionals after evaluating the need of the patient.
Application Insights:
Based on the application, the market is segmented into hospital, clinic and other. The hospital segment dominated the overall industry in terms of revenue in 2017 owing to factors such as high prevalence of chronic hepatitis C patients and increasing awareness about HCV infection among individuals at risk. Moreover, an increase in spending capacity by governments as well as private organizations to develop state-of-the-art facilities for treatment will further propel growth over the forecast period.
The other application segment includes home healthcare services and non-residential settings that offer direct patient access to medication management without any extra cost or charge. This type of service is provided by a multidisciplinary team including medical professionals along with support staff such as nutritionists, social workers and counselors who are all working together toward a common goal - improving quality of life for patients suffering from chronic hepatitis C virus (HCV) infection through early diagnosis & effective treatment at an affordable cost.
Regional Analysis:
North America dominated the global hepatitis C treatment market in 2017. This can be attributed to the presence of a large number of players, high awareness levels coupled with rising prevalence of HCV infection. The U.S is one of the most affected countries due to this disease as around 2 million people are suffering from it and over half die due to it every year in this country alone which is one of the highest rates worldwide. In addition, there are around 14 million people living with chronic hepatitis C virus (HCV) infection in U.S., who have no idea about their status and do not take any treatment for it thinking they will get cured by themselves or through natural course thus increasing their risk for serious health complications like liver failure, etc’s leading to higher death rate also known as hepatic morbidity & mortality rate (HMMR).
Asia Pacific region is expected to witness lucrative growth over the forecast period owing its huge population base suffering from different forms.
Growth Factors:
- Increasing incidence of hepatitis C infections: The global incidence of hepatitis C is estimated to be around 71 million, and the number of new cases is projected to grow at a rate of 2-3% per year. This will create demand for new and innovative therapies for the treatment of hepatitis C.
- Growing awareness about available treatments: There is growing awareness among patients and healthcare professionals about the availability of effective treatments for hepatitis C. This is driving demand for these therapies, especially in developed markets such as the US and Europe.
- Launch of novel direct-acting antiviral agents: A number of novel direct-acting antiviral agents (DAAs) have been launched in recent years, offering improved efficacy and safety profiles over older generation therapies. This is helping to drive growth in the hepatits C treatment market worldwide.
Scope Of The Report
Report Attributes
Report Details
Report Title
Hepatitis C Treatment Market Research Report
By Type
Rx, OTC
By Application
Hospital, Clinic, Other
By Companies
AbbVie, Gilead, Kenilworth, Merck, Johnson & Johnson, Bristol-Myers Squibb
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
207
Number of Tables & Figures
145
Customization Available
Yes, the report can be customized as per your need.
Global Hepatitis C Treatment Market Report Segments:
The global Hepatitis C Treatment market is segmented on the basis of:
Types
Rx, OTC
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AbbVie
- Gilead
- Kenilworth
- Merck
- Johnson & Johnson
- Bristol-Myers Squibb
Highlights of The Hepatitis C Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Rx
- OTC
- By Application:
- Hospital
- Clinic
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Hepatitis C Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There is no cure for hepatitis C, but there are treatments that can help manage the disease. Treatment options include antiviral medications, liver transplantation, and a combination of both.
Some of the major players in the hepatitis c treatment market are AbbVie, Gilead, Kenilworth, Merck, Johnson & Johnson, Bristol-Myers Squibb.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Hepatitis C Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Hepatitis C Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Hepatitis C Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Hepatitis C Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Hepatitis C Treatment Market Size & Forecast, 2020-2028
4.5.1 Hepatitis C Treatment Market Size and Y-o-Y Growth
4.5.2 Hepatitis C Treatment Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Rx
5.2.2 OTC
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Hepatitis C Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Hepatitis C Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Rx
9.6.2 OTC
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Rx
10.6.2 OTC
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Rx
11.6.2 OTC
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Rx
12.6.2 OTC
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Rx
13.6.2 OTC
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Hepatitis C Treatment Market: Competitive Dashboard
14.2 Global Hepatitis C Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AbbVie
14.3.2 Gilead
14.3.3 Kenilworth
14.3.4 Merck
14.3.5 Johnson & Johnson
14.3.6 Bristol-Myers Squibb
